VIDEO: Topical treatments may be effective against moderate to severe atopic dermatitis

In this video, Raj Chovatiya, MD, PhD, discussed research into the OX40 inhibitor amlitelimab, as well as two topical medications, from the Maui Derm 2024 meeting, examining data into their use in treating atopic dermatitis.

Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed data on roflumilast, which is already approved for psoriasis, as well as phase 3 data on tapinarof (Vtama, Dermavant).

“In a topical format you may be actually able to treat a wide variety of individuals that have more moderate-to-severe disease as opposed to the mild to moderate that we are really used to as well,” Chovatiya said.